Mirum's liver infection drug lowers virus levels in second late-stage study
MIRM•Mirum Pharmaceuticals said brelovitug met the main goal in a second late-stage hepatitis delta study, with 59% of patients achieving reduced virus levels and normal liver enzyme levels after 24 weeks, versus none in the delayed-treatment group.
1. Study results
Mirum Pharmaceuticals said its experimental hepatitis delta treatment brelovitug met the main goal of a second late-stage study. After 24 weeks, 59% of patients receiving weekly treatment achieved reduced virus levels and normal liver enzyme levels, compared with none in the delayed-treatment group.
2. Approval plans and safety
The study enrolled 113 previously untreated patients, more than half of whom had cirrhosis. Mirum said the study is the second of two supporting its planned U.S. approval application, expected in the first half of 2027. Longer-term data showed all 15 cirrhosis patients treated for up to 108 weeks achieved the two outcomes. The company reported no new safety concerns; flu-like illness was the most common side effect.
